Novo’s CEO Turns to Next Targets After Losing Metsera to Pfizer

Novo Nordisk A/S Chief Executive Officer Mike Doustdar may have lost out to Pfizer Inc. in a $10 billion takeover battle for obesity drug developer Metsera Inc. But don’t expect...

By Eric Pfanner, Aaron Kirchfeld, Naomi Kresge · Bloomberg

Novo Nordisk A/S Chief Executive Officer Mike Doustdar may have lost out to Pfizer Inc. in a $10 billion takeover battle for obesity drug developer Metsera Inc. But don’t expect him to give up on dealmaking any time soon as the Danish company seeks to regain lost ground in the booming weight-loss market.